Related Experiment Video
Updated: Jul 15, 2025
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.6K
Status Cataplecticus Induced by an Abrupt Duloxetine Withdrawal-A Case Report
Marek Cierny1, John Feemster2, Mohsin Hamid3
1Department of Neurology, Medical College of Wisconsin, Milwaukee.
Clinical Neuropharmacology
|September 25, 2023
Summary
Sudden antidepressant withdrawal can trigger status cataplecticus in narcolepsy type 1 patients. This case highlights duloxetine withdrawal as a cause, emphasizing the need for gradual dose reduction and patient counseling.
Area of Science:
- Neurology
- Pharmacology
Background:
- Narcolepsy type 1 is a chronic neurological disorder.
- Antidepressant withdrawal can precipitate neurological complications.
Observation:
- A 77-year-old female with narcolepsy type 1 experienced recurrent paralysis episodes.
- These episodes began after abrupt discontinuation of duloxetine.
Findings:
- This is the first reported case of status cataplecticus linked to duloxetine withdrawal.
- Symptoms resolved upon duloxetine resumption and hypokalemia treatment.
Implications:
- Physicians should counsel narcolepsy patients on antidepressant withdrawal risks.
- Gradual dose tapering of antidepressants is crucial in narcolepsy type 1 management.
Related Concept Videos
01:20Desensitization and Tachyphylaxis
1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
428
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
428
01:17Drugs for Treatment of Diarrhea-Predominant IBS
200
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
200
01:21Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
01:28Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
20
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
20